Desferrioxamine Mesylate (DBL) is a medicine containing the active ingredient(s) desferrioxamine. On this page you will find out more about Desferrioxamine Mesylate (DBL), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: desferrioxamine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Desferrioxamine Mesylate (DBL) 2 g powder for injection, 1 vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Chronic Iron Overload. Desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. Long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. The drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. Desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. Acute iron poisoning: Desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, suction and maintenance of a clear airway, control of shock with intravenous fluids, blood, oxygen and vasopressor and correction of acidosis.
Table of characteristics
|Visual appearance||White to cream powder or lyophilised plug.|
|Dosage Form||Injection, powder for|
|Route of administration||Intravenous|
1 x 50mL vial: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Light|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 January 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
DBL Desferrioxamine Mesylate for Injection BP (Powder for injection) - myDr.com.au
DBL Desferrioxamine Mesylate for Injection BP (Powder for injection) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 0 results